[go: up one dir, main page]

DK3830085T3 - Deutereret derivat af lanifibranor - Google Patents

Deutereret derivat af lanifibranor Download PDF

Info

Publication number
DK3830085T3
DK3830085T3 DK19759658.8T DK19759658T DK3830085T3 DK 3830085 T3 DK3830085 T3 DK 3830085T3 DK 19759658 T DK19759658 T DK 19759658T DK 3830085 T3 DK3830085 T3 DK 3830085T3
Authority
DK
Denmark
Prior art keywords
lanifibranor
deuterated derivative
deuterated
derivative
Prior art date
Application number
DK19759658.8T
Other languages
English (en)
Inventor
Christian Montalbetti
Benaissa Boubia
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Application granted granted Critical
Publication of DK3830085T3 publication Critical patent/DK3830085T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK19759658.8T 2018-07-27 2019-07-26 Deutereret derivat af lanifibranor DK3830085T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1857021A FR3084254B1 (fr) 2018-07-27 2018-07-27 Derives deuteres du lanifibranor
PCT/FR2019/051860 WO2020021215A1 (fr) 2018-07-27 2019-07-26 Derives deuteres du lanifibranor

Publications (1)

Publication Number Publication Date
DK3830085T3 true DK3830085T3 (da) 2024-01-22

Family

ID=63684156

Family Applications (2)

Application Number Title Priority Date Filing Date
DK23201458.9T DK4331584T3 (da) 2018-07-27 2019-07-26 Terapeutiske anvendelser af deutererede derivater af lanifibranor
DK19759658.8T DK3830085T3 (da) 2018-07-27 2019-07-26 Deutereret derivat af lanifibranor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK23201458.9T DK4331584T3 (da) 2018-07-27 2019-07-26 Terapeutiske anvendelser af deutererede derivater af lanifibranor

Country Status (19)

Country Link
US (2) US12291526B2 (da)
EP (2) EP3830085B1 (da)
JP (2) JP7434278B2 (da)
CN (1) CN112638911B (da)
DK (2) DK4331584T3 (da)
ES (2) ES3014955T3 (da)
FI (2) FI4331584T3 (da)
FR (1) FR3084254B1 (da)
HR (2) HRP20250340T8 (da)
HU (2) HUE065045T2 (da)
LT (2) LT3830085T (da)
MA (1) MA67726B1 (da)
MD (1) MD4331584T2 (da)
PL (2) PL3830085T3 (da)
PT (2) PT4331584T (da)
RS (2) RS65095B1 (da)
SI (2) SI4331584T1 (da)
SM (2) SMT202500113T1 (da)
WO (1) WO2020021215A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102199640B1 (ko) * 2020-01-06 2021-01-07 브렉소젠 주식회사 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물
EP4000616A1 (en) * 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022143479A1 (zh) * 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
MX2024001745A (es) * 2021-08-12 2024-04-10 Crystal Pharmaceutical Suzhou Co Ltd Forma cristalina de lanifibranor, método de preparación del mismo y su uso.
IL322148A (en) 2023-01-19 2025-09-01 Inventiva Formulation of Lenifibernor
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AU2023451557A1 (en) 2023-06-06 2026-01-15 Inventiva Use of adiponectin, ferritin, mmp9 and transferrin for monitoring liver disease treatment with lanifibranor
AU2023451460A1 (en) 2023-06-06 2026-01-15 Inventiva Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment with lanifibranor
TW202519213A (zh) 2023-09-22 2025-05-16 法商因文帝華公司 蘭尼菲諾(lanifibranor)之製造方法
WO2025132989A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025132955A1 (en) 2023-12-21 2025-06-26 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
TW202543596A (zh) 2024-03-15 2025-11-16 法商因文帝華公司 預防接受過氧化物酶體增生劑活化受體(ppar)促效劑治療患者之血液病症

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
MX373268B (es) 2014-06-13 2020-04-16 Inventiva Compuestos ppar para uso en el tratamiento de enfermedades fibroticas.
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
WO2018039521A1 (en) 2016-08-26 2018-03-01 Concert Pharmaceuticals, Inc. Deuterated cenicriviroc
US11504380B2 (en) * 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis

Also Published As

Publication number Publication date
RS65095B1 (sr) 2024-02-29
WO2020021215A1 (fr) 2020-01-30
US20250263406A1 (en) 2025-08-21
FR3084254A1 (fr) 2020-01-31
FR3084254B1 (fr) 2020-10-23
HRP20250340T1 (hr) 2025-05-09
SMT202500113T1 (it) 2025-05-12
LT4331584T (lt) 2025-03-25
ES3014955T3 (en) 2025-04-28
EP4331584B1 (fr) 2025-01-01
LT3830085T (lt) 2024-02-12
SMT202400053T1 (it) 2024-03-13
US12291526B2 (en) 2025-05-06
MA67726B1 (fr) 2025-04-30
HRP20240157T1 (hr) 2024-04-12
DK4331584T3 (da) 2025-03-17
PL4331584T3 (pl) 2025-04-28
CN112638911A (zh) 2021-04-09
RS66614B1 (sr) 2025-04-30
SI3830085T1 (sl) 2024-03-29
HUE065045T2 (hu) 2024-04-28
SI4331584T1 (sl) 2025-04-30
JP2021533101A (ja) 2021-12-02
JP2024036611A (ja) 2024-03-15
HRP20250340T8 (hr) 2025-06-20
PT4331584T (pt) 2025-02-27
US20210300913A1 (en) 2021-09-30
JP7434278B2 (ja) 2024-02-20
CN112638911B (zh) 2024-07-19
PL3830085T3 (pl) 2024-04-15
JP7637281B2 (ja) 2025-02-27
EP3830085A1 (fr) 2021-06-09
PT3830085T (pt) 2024-01-24
FI4331584T3 (fi) 2025-04-01
HUE070489T2 (hu) 2025-06-28
EP3830085B1 (fr) 2023-11-08
MD4331584T2 (ro) 2025-11-30
FI3830085T3 (fi) 2024-01-17
EP4331584A1 (fr) 2024-03-06
ES2970597T3 (es) 2024-05-29

Similar Documents

Publication Publication Date Title
DK3830085T3 (da) Deutereret derivat af lanifibranor
DK3810581T3 (da) Krystalmodifikationer af odevixibat
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
DK3382551T3 (da) Sporing af fordelt hardware
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3978483T3 (da) Krystallinsk toluensolvat af (s)-afoxolaner
DK4067344T3 (da) Cycloalkylurinstofderivat
EP3816714A4 (en) GLASSES GLASS
DK3457851T3 (da) Derivater af sobetirom
DK3943070T3 (da) Langtidsvirkende formuleringer af bedaquilin
DK3678648T3 (da) Fremgangsmåder til anvendelse af dipivefrin
DK3474822T3 (da) Formuleringer af brincidofovir
DK3523315T3 (da) Inhibitor af glucocorticoidreceptor
DK3508793T3 (da) Komfurbeskyttelse under anvendelse af bredt synsfelt
DK3717503T3 (da) Albumin-bindende prodrugs af auristatin E derivater
EP3785678A4 (en) STENT
DK3636640T3 (da) Krystal af heterocyclidenacetamidderivat
EP3885347A4 (en) DIHYDROPYRROLOPYRAZOLE DERIVATIVE
EP3617195A4 (en) NEW TETRAHYDRONAPHTYL UREA DERIVATIVES
KR20210030271A9 (ko) 스텐트
DK3678644T3 (da) Formuleringer af copanlisib
DK3743064T3 (da) Behandling af proteinuri
DK3749673T3 (da) Krystallinsk form af bictegravir-natrium
EP3700466A4 (en) INTRAOCULAR LENS
EP3770162A4 (en) DIHYDROCHROME DERIVATIVE